Research highlights the antifibrotic effects of N-acetylcysteine in fibroblasts from chronic wounds associated with recessive dystrophic epidermolysis bullosa. This study may inform future therapeutic strategies for managing fibrosis in this rare skin condition.

The Prospective Epidermolysis Bullosa Longitudinal Evaluation Study (PEBLES) reveals significant insights into health-related quality of life for patients with recessive dystrophic epidermolysis bullosa. This study contributes valuable data to understanding the patient experience in this rare skin condition.

A case report highlights the challenges of managing recessive dystrophic epidermolysis bullosa in a resource-limited setting at Mohamed Adam Sheikh Children's Teaching Hospital in Hargeisa, Somaliland. This study underscores the need for improved healthcare resources for rare diseases in underserved regions.

INmune Bio will present new clinical data on CORDStrom™ for recessive dystrophic epidermolysis bullosa (RDEB) in an upcoming webinar. The MissionEB Phase III trial highlights CORDStrom™ as a systemic, disease-modifying therapy, contrasting with current treatments that focus solely on topical wound care.